Soligenix announces promising results in extended HyBryte treatment study for cutaneous T-cell lymphoma
Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company, has shared an interim update on a key study involving extended HyBryte treatment in patients with early-stage cutaneous T-cell lymphoma (CTCL). This ongoing study, led by Dr. Ellen Kim, MD, of the Hospital of the University of Pennsylvania, showcases promising results with HyBryte therapy over periods extending […]